Prometrium vs Compounded Micronized Progesterone: A Clinical Comparison

What Is Prometrium and Why Does the Compounded Version Exist?

Prometrium is the only FDA-approved oral formulation of micronized progesterone in the United States. Abbott (now AbbVie) received approval in 1998. The drug contains 100 mg or 200 mg of micronized progesterone suspended in peanut oil inside a gelatin capsule.

Compounded micronized progesterone exists for several practical reasons: patients with peanut allergies cannot use Prometrium, some patients want non-oral delivery routes such as sublingual or vaginal cream, and the cost differential is real. A 30-day supply of branded Prometrium 200 mg can exceed $150 at retail without insurance, while a compounding pharmacy may charge $40, $70 for the equivalent cycle supply.

The Molecule Itself

Both products use the same active pharmaceutical ingredient: progesterone, micronized to particle sizes below 20 microns to improve dissolution and absorption. Micronization dramatically increases surface area compared to unmicronized progesterone powder. This matters because progesterone is highly lipophilic and dissolves poorly in aqueous environments; smaller particles dissolve faster in the peanut oil (Prometrium) or the compounding vehicle.

The molecule is bioidentical, meaning its chemical structure is identical to endogenous human progesterone. This distinguishes both products from synthetic progestins such as medroxyprogesterone acetate (MPA), norethindrone, and levonorgestrel, which have measurably different receptor-binding profiles and cardiovascular signal patterns. [1]

Why the Distinction Between "Bioidentical" and "Compounded" Matters

These two terms are frequently conflated in direct-to-consumer marketing, and the confusion has clinical consequences. Prometrium is bioidentical and FDA-approved. Compounded progesterone may also be bioidentical but is not FDA-approved as a finished drug product. The Endocrine Society's 2016 position statement states: "The FDA has approved bioidentical estradiol and progesterone formulations. Compounded bioidentical hormones are not FDA-approved and have not been shown to be safer or more effective than FDA-approved menopausal hormone therapies." [2]

Bioavailability: How Much Progesterone Actually Reaches Circulation?

Oral micronized progesterone undergoes extensive first-pass hepatic metabolism. Absolute oral bioavailability is approximately 10%, though this figure varies considerably with food intake. Taking Prometrium with a high-fat meal raises peak serum progesterone (Cmax) by roughly 3-fold compared to fasting. [3]

Prometrium Pharmacokinetics

After a single 200 mg oral dose of Prometrium in healthy postmenopausal women, Cmax is approximately 17.3 ng/mL at a Tmax of 1.5 hours. The half-life of the parent compound is about 16 to 18 hours. Serum levels return to baseline within 24 hours of dosing, which is why nightly administration is standard.

The peanut oil vehicle in Prometrium is not incidental. Oil-in-capsule formulations slow gastric emptying and improve lymphatic absorption of lipophilic drugs. A study published in Fertility and Sterility (Levine et al., 2000) found that the peanut oil vehicle contributed meaningfully to consistent inter-patient absorption relative to powder-in-capsule compounded formulations. [4]

Compounded Oral Capsules

Compounded oral capsules typically use one of three vehicles: peanut oil (same as Prometrium), sunflower oil, or a powder fill with a wetting agent. Oil-filled compounded capsules generally perform closest to Prometrium in pharmacokinetic terms. Dry powder-fill capsules show more variable absorption, with some pharmacokinetic studies reporting Cmax values 20 to 40% lower than equivalent Prometrium doses. [5]

This variability is not trivial in the HRT context. Endometrial protection depends on adequate serum and tissue progesterone exposure over time. A compounded product that delivers reliably lower peak levels could theoretically leave the endometrium incompletely protected in women with an intact uterus receiving systemic estrogen.

Non-Oral Compounded Routes

Vaginal progesterone cream and vaginal suppositories deliver progesterone with a "first-uterine-pass" effect: high local endometrial concentrations with relatively low systemic serum levels. This is well-established for fertility applications using products like Crinone (8% progesterone gel, FDA-approved) and Endometrin (progesterone 100 mg vaginal insert, FDA-approved). [6]

Transdermal progesterone creams, by contrast, are a different matter. Multiple studies show that standard over-the-counter or compounded progesterone creams produce serum levels far below the threshold needed for endometrial protection. A 2005 study by Burry et al. Found salivary progesterone rose with cream use but serum progesterone remained essentially unchanged at concentrations inadequate to oppose estrogen at the endometrium. [7] Topical cream should not be relied on for endometrial protection in women receiving systemic estrogen.

The PEPI Trial: The Foundational Evidence Base

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995, remains the most cited randomized controlled trial comparing micronized progesterone to synthetic progestins in postmenopausal women. [1]

Trial Design and Population

PEPI enrolled 875 healthy postmenopausal women aged 45 to 64 at seven clinical centers across the United States. Participants were randomized to one of five arms: placebo, conjugated equine estrogens (CEE) 0.625 mg alone, CEE plus MPA 10 mg cyclic, CEE plus MPA 2.5 mg continuous, or CEE plus micronized progesterone (MP) 200 mg cyclic. Follow-up was 3 years.

The primary outcomes were HDL cholesterol, systolic blood pressure, insulin, and fibrinogen. Endometrial safety was a key secondary endpoint evaluated by annual biopsy.

What PEPI Found

In the lipid analysis, CEE plus MP produced a significantly better HDL-cholesterol profile than CEE plus either MPA regimen. The MP arm raised HDL by 1.6 mg/dL from baseline compared to a rise of 1.2 mg/dL with CEE plus continuous MPA (P<0.001 for the comparison between MP and MPA arms). [1]

Endometrial protection was equivalent across all progestin-containing arms. Adenomatous or atypical hyperplasia rates were low and statistically similar between MP and both MPA arms. Unopposed CEE produced endometrial hyperplasia in 34% of participants by year 3, confirming the necessity of progestogen opposition in women with a uterus.

The PEPI data also showed that micronized progesterone had a neutral-to-favorable effect on fibrinogen compared to MPA, a finding that generated interest in whether bioidentical progesterone might carry a different cardiovascular risk profile than synthetic progestins. Those hypotheses remain incompletely resolved at the level of hard cardiovascular outcomes.

Limitations of PEPI for the Compounded vs Branded Question

PEPI used the specific Prometrium formulation, not a compounded equivalent. Extrapolating PEPI's endometrial safety data to compounded micronized progesterone requires assuming bioequivalence between the two products. That assumption is pharmacokinetically plausible for oil-filled compounded capsules but less defensible for powder-fill capsules or topical cream.

Manufacturing Standards: FDA Oversight vs Compounding Pharmacy Regulation

This is the sharpest practical difference between the two products. Prometrium is manufactured under Current Good Manufacturing Practice (cGMP) regulations enforced by the FDA. Every batch is tested for potency, sterility, dissolution, and uniformity before release. Deviations trigger recalls.

503A vs 503B Compounding

Compounding pharmacies in the United States operate under one of two frameworks. Section 503A of the Food, Drug, and Cosmetic Act governs traditional patient-specific compounding. These pharmacies are primarily regulated by state boards of pharmacy, not the FDA, and are not required to meet cGMP standards. Section 503B "outsourcing facilities" must meet cGMP requirements and are subject to FDA inspections, but they produce non-patient-specific bulk compounding. [8]

A 2012 fungal meningitis outbreak linked to contaminated compounded methylprednisolone from a 503A pharmacy killed 64 patients and injured more than 700. While that involved a different drug, the event catalyzed regulatory reform via the Drug Quality and Security Act of 2013 and remains the defining illustration of what inadequate manufacturing oversight can produce.

The FDA conducted a study of 29 compounded hormone preparations in 2001 and found that 10 of 29 samples (34%) failed potency testing. Four preparations had potencies below 75% of label claim. [9] A follow-up surveillance study reported similar variability. This does not mean all compounded progesterone is subpotent, but it establishes that inter-pharmacy variability is a genuine clinical risk.

What This Means at the Prescriber Level

When a clinician prescribes Prometrium 200 mg, they can be confident the patient receives 200 mg of micronized progesterone in a consistent peanut oil vehicle, batch after batch. When a clinician prescribes compounded micronized progesterone 200 mg, the actual delivered dose depends heavily on which pharmacy fills it, the vehicle chosen, and that pharmacy's quality systems.

For prescribers using compounding pharmacies, choosing an accredited pharmacy (PCAB accreditation from the Pharmacy Compounding Accreditation Board) reduces but does not eliminate this risk. Requesting a certificate of analysis (CoA) for each batch is reasonable clinical practice.

Clinical Scenarios Where Compounded Progesterone May Be Appropriate

The following framework reflects HealthRX clinical team guidance for deciding between Prometrium and a compounded alternative. It is intended for use by prescribing clinicians and should be applied in the context of a full clinical evaluation.

Scenario 1: Peanut allergy. Prometrium is contraindicated. A compounded oil-filled capsule in sunflower, sesame, or MCT oil is the appropriate substitute. Confirm with the compounding pharmacy that peanut oil is excluded from the facility entirely, not just from the formulation.

Scenario 2: Swallowing difficulty or capsule aversion. A sublingual compounded micronized progesterone formulation bypasses first-pass metabolism and delivers higher serum progesterone per milligram. Dose adjustments are required; 100 mg sublingual is not equivalent to 100 mg oral. Serum progesterone monitoring at 4 to 6 weeks is advisable to confirm adequate exposure.

Scenario 3: Vaginal route for fertility support. FDA-approved vaginal progesterone products (Crinone, Endometrin) should be used when available and affordable. Compounded vaginal progesterone suppositories 200 to 400 mg are a reasonable alternative when cost is prohibitive, given the well-established uterine first-pass effect for luteal support.

Scenario 4: Cost-driven switch in a stable patient. If a patient is established on Prometrium with documented endometrial protection and tolerable side effects, switching to a high-quality, PCAB-accredited pharmacy's oil-filled compounded equivalent is a reasonable cost-reduction strategy. Repeat endometrial biopsy or pelvic ultrasound at 6 months post-switch is advisable in women with a uterus receiving systemic estrogen.

Scenario 5: Topical cream for endometrial protection. This scenario has no clinical justification. Topical progesterone cream does not reliably achieve serum levels sufficient to protect the endometrium. It should not be prescribed for this indication.

Side-Effect Profile: Is There a Meaningful Difference?

Both products share the same side-effect profile because the active molecule is identical. The most common adverse effects are somnolence, dizziness, breast tenderness, and irregular bleeding, particularly during cycle initiation. Prometrium's package insert reports somnolence in up to 45% of patients at 400 mg/day dosing (used in the original endometrial protection studies). [10]

Somnolence as a Clinical Feature

The sedating effect of oral micronized progesterone is mediated through its metabolite 3-alpha-hydroxy-5-alpha-pregnan-20-one (allopregnanolone), a positive allosteric modulator of GABA-A receptors. This is not a side effect to suppress; many patients find the nighttime sedation beneficial, particularly in the menopausal transition when sleep disruption is common. Taking the dose at bedtime is standard practice.

Compounded sublingual formulations may produce less somnolence per milligram because higher serum progesterone is achieved with a smaller dose, but allopregnanolone conversion still occurs. Patients reporting no sedation from sublingual progesterone may be under-dosed.

Bleeding Patterns

Cyclic administration of 200 mg for 12 days per cycle produces scheduled withdrawal bleeding in most women with a uterus. Continuous 100 mg nightly dosing aims for amenorrhea but produces irregular spotting in approximately 30 to 50% of patients during the first 3 to 6 months. Both patterns apply equally to Prometrium and compounded oral equivalents.

Cost Analysis

Prometrium 200 mg, 30 capsules (a one-cycle supply for cyclic dosing) retails at approximately $80, $180 depending on pharmacy and location, without insurance. With GoodRx or similar discount programs, prices at some pharmacies fall to $55, $90. Most commercial insurance plans cover Prometrium at a Tier 2 or Tier 3 copay.

Compounded micronized progesterone 200 mg, 30 capsules from a PCAB-accredited pharmacy typically costs $35, $75 without insurance. For patients without drug coverage or with high-deductible plans, the savings are real and cumulative across months of therapy.

The cost comparison should also account for monitoring. A patient who switches to a compounded formulation with uncertain bioavailability may require additional serum progesterone testing or endometrial surveillance, adding cost that partially offsets the medication savings.

Current Regulatory and Clinical Guideline Positions

The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement acknowledges micronized progesterone as preferred over synthetic progestins for progestogen opposition in HRT, citing the more favorable lipid and possibly breast safety data. [11] The statement endorses FDA-approved Prometrium as the evidence-based choice and notes that compounded hormones should be reserved for specific clinical situations where approved products are inadequate.

The Endocrine Society similarly recommends against routine use of compounded hormone preparations in the absence of a medical indication that cannot be met by approved products. [2]

Neither organization has issued guidelines that endorse compounded topical progesterone for endometrial protection. The FDA's position, stated in multiple drug safety communications, is that compounded preparations should not be used when an approved drug that meets the patient's needs is already available. [8]

Monitoring Progesterone Levels: When and Why

Serum progesterone measurement is not routinely required for patients stable on Prometrium. The FDA-approved formulation's pharmacokinetics are well-characterized. However, serum monitoring is appropriate in the following situations: switching from Prometrium to a compounded product, using a sublingual or non-oral compounded route, persistent irregular bleeding in a patient on continuous dosing, or any clinical concern about endometrial exposure adequacy.

Timing of the blood draw matters. Because oral micronized progesterone has a Tmax of 1.5 hours and returns to baseline within 24 hours, a serum progesterone drawn on a non-dosing day will be near zero and is not clinically informative. Draw timing should be 2 to 4 hours post-dose to capture near-peak levels, or at a consistent trough time (12 to 16 hours post-dose) to establish a steady-state baseline for serial comparisons.

A serum progesterone level above 5 ng/mL at 2 to 4 hours post-dose of 200 mg oral micronized progesterone suggests adequate absorption. Levels persistently below 3 ng/mL in a patient with a uterus receiving systemic estrogen warrant formulation review or dose adjustment.